Cellipont Bioservices Appoints Brett Reynolds as Chief Financial Officer to Lead Financial Strategy and Support Growth in Cell Therapy CDMO Sector
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Brett Reynolds as its new Chief Financial Officer, effective immediately. Mr. Reynolds has over 25 years of experience in financial leadership roles, primarily in the life sciences industry, and succeeds Tim Heher, who recently retired from the Company.
In his new role, Mr. Reynolds will be responsible for overseeing Cellipont’s overall financial strategy and leading the finance and information technology organizations. Leveraging his extensive background as a CFO in multiple high-growth businesses, Mr. Reynolds will play a pivotal role in supporting the company’s strategic growth and expansion goals. He brings expertise in profitability and cash flow enhancement, financial planning and analysis, revenue growth, mergers and acquisitions, financial systems, fundraising, and board and investor relations.
Mr. Reynolds served as CFO of EndoGastric Solutions, a medical device company focused on developing and commercializing innovative technologies for the treatment of gastroesophageal reflux disease, until its acquisition by Merit Medical in July 2024. Prior to EGS, Mr. Reynolds served as Chief Financial Officer of Resonetics, a diversified high-growth med-tech CDMO, from 2019 to 2023. Before that, he held CFO roles at Cogentix Medical and Synovis Life Technologies. He is a Certified Public Accountant (inactive) and holds a bachelor’s degree in accounting and an MBA in finance, both from the University of Minnesota.
“Brett’s extensive experience in high-growth organizations makes him the ideal leader to help guide Cellipont through its next chapter of expansion,” said Darren Head, CEO of Cellipont Bioservices. “His expertise will be critical as we scale our operations and continue to advance innovative solutions for our clients and the patients they serve.”
“I am excited to join Cellipont, a premier cell therapy CDMO committed to exceeding client expectations and advancing patient care. I look forward to working with the company’s world-class management team as we support our clients in their drive to bring life-changing treatments to those in need,” said Brett Reynolds, Chief Financial Officer.
About Cellipont
Cellipont Bioservices is a premier Contract Development and Manufacturing Organization (CDMO) specializing in the advancement of cell therapies. With a team of industry-leading experts, Cellipont is at the forefront of cell therapy development and manufacturing, offering comprehensive solutions from process development, analytical services, to large-scale commercial manufacturing. Our purpose-built facility, combined with our cutting-edge technology and commitment to quality enable us to support our clients in delivering life-changing cell therapies to patients worldwide. Cellipont Bioservices is dedicated to excellence in all aspects of our operations, ensuring that we not only meet but exceed the expectations of our clients and the communities we serve. To learn more, visit www.cellipont.com.
Cellipont Media Contact
Edwin Beale
CCO
[email protected]